Bio-Techne Saham

Bio-Techne EBITDA

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Bio-Techne (TECH) pada 12 Agu 2026 adalah 138,27 Juta. USD. Tahun sebelumnya, EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah 239,89 Juta. USD — perubahan sebesar -42,36% (lebih rendah).

EBITDA

138,27 Juta.USD

YoY

-42,36%

Terakhir Diperbarui:

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Bio-Techne adalah 2026 138,27 Juta. USD. EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Bio-Techne adalah 2025 239,89 Juta. USD. Menurun -42,36% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Bio-Techne Analisis saham

Apa yang dilakukan Bio-Techne? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Bio-Techne

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Bio-Techne adalah 138,27 Juta. USD pada tahun 2026.

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Bio-Techne berubah dari 239,89 Juta. USD menjadi 138,27 Juta. USD, mewakili perubahan -42,36%. Nilainya lebih rendah daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Bio-Techne sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

EBITDA mengukur kinerja operasional sebelum dampak struktur keuangan, lingkungan pajak, dan biaya penyusutan non-kas.

EBITDA = EBIT + Penyusutan & Amortisasi

USD EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak Bio-Techne EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) secara historis dan real-time.

Access this data via the Eulerpool API

Laporan Laba Rugi — Bio-Techne

Semua Metrik Kunci — Bio-Techne